US Bancorp DE increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.8% during the second quarter, Holdings Channel reports. The firm owned 4,224 shares of the medical research company’s stock after buying an additional 34 shares during the period. US Bancorp DE’s holdings in Bio-Rad Laboratories were worth $956,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in Bio-Rad Laboratories by 6.8% in the first quarter. Bank of New York Mellon Corp now owns 244,936 shares of the medical research company’s stock worth $48,826,000 after buying an additional 15,496 shares during the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in Bio-Rad Laboratories during the first quarter worth approximately $1,253,000. Great West Life Assurance Co. Can increased its stake in Bio-Rad Laboratories by 3.9% in the first quarter. Great West Life Assurance Co. Can now owns 12,380 shares of the medical research company’s stock worth $2,467,000 after buying an additional 469 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in Bio-Rad Laboratories by 23.8% in the first quarter. Parametric Portfolio Associates LLC now owns 90,855 shares of the medical research company’s stock worth $18,111,000 after buying an additional 17,492 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC increased its stake in Bio-Rad Laboratories by 804.7% in the first quarter. Quantitative Systematic Strategies LLC now owns 11,037 shares of the medical research company’s stock worth $2,201,000 after buying an additional 9,817 shares during the last quarter. Hedge funds and other institutional investors own 63.73% of the company’s stock.

Bio-Rad Laboratories, Inc. (BIO) traded down 1.52% during mid-day trading on Thursday, reaching $215.61. 53,261 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $229.69 and its 200 day moving average is $212.16. The stock has a market capitalization of $6.39 billion, a PE ratio of 426.11 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 1-year low of $147.68 and a 1-year high of $242.79.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/bio-rad-laboratories-inc-nysebio-shares-bought-by-us-bancorp-de/1471335.html.

BIO has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price objective for the company in a report on Monday, May 1st. Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their price objective for the company from $220.00 to $195.00 in a report on Wednesday, June 28th. BidaskClub upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Jefferies Group LLC reiterated a “buy” rating and issued a $250.00 price objective on shares of Bio-Rad Laboratories in a report on Thursday, April 27th. Finally, Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $228.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.